Penumbra (NYSE:PEN) Shares Break Below 50 Day Moving Average – What’s Next?

Shares of Penumbra, Inc. (NYSE:PEN – Get Free Report) crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $320.15 and traded as low as $319.05. Penumbra shares last traded at $319.4290, with a volume of 365,983 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Canaccord Genuity Group reissued a “hold” rating and set a $374.00 price target on shares of Penumbra in a report on Tuesday. Weiss Ratings raised Penumbra from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, October 30th. Finally, Zacks Research raised Penumbra from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. Three investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $367.07.

View Our Latest Stock Analysis on Penumbra

Penumbra Trading Down 0.4%

The company has a market cap of $12.59 billion, a PE ratio of 80.46 and a beta of 0.71. The stock’s 50 day moving average is $320.15 and its 200-day moving average is $325.71. The company has a quick ratio of 3.92, a current ratio of 5.89 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $1.07 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.13). The business had revenue of $410.15 million during the quarter, compared to the consensus estimate of $401.41 million. Penumbra had a return on equity of 10.39% and a net margin of 10.06%. The business’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.97 earnings per share. As a group, sell-side analysts anticipate that Penumbra, Inc. will post 4.96 EPS for the current year.

Institutional Investors Weigh In On Penumbra

Large investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC lifted its holdings in Penumbra by 7.1% during the 3rd quarter. Parallel Advisors LLC now owns 514 shares of the company’s stock worth $164,000 after buying an additional 34 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in Penumbra by 48.7% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 116 shares of the company’s stock valued at $37,000 after buying an additional 38 shares during the period. North Dakota State Investment Board grew its stake in shares of Penumbra by 3.5% in the third quarter. North Dakota State Investment Board now owns 1,166 shares of the company’s stock worth $371,000 after acquiring an additional 39 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Penumbra by 0.6% in the third quarter. Oregon Public Employees Retirement Fund now owns 8,130 shares of the company’s stock worth $2,588,000 after acquiring an additional 49 shares in the last quarter. Finally, Bessemer Group Inc. grew its stake in shares of Penumbra by 37.8% in the third quarter. Bessemer Group Inc. now owns 237 shares of the company’s stock worth $76,000 after acquiring an additional 65 shares in the last quarter. 88.88% of the stock is owned by institutional investors.

About Penumbra

(Get Free Report)

Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.

Featured Stories

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.